Stéphanie Blanchard

Discovery of the Macrocycle 11-(2-Pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene (SB1518), a Potent Janus Kinase 2/Fms-Like Tyrosine Kinase-3 (JAK2/FLT3) Inhibitor for the Treatment of Myelofibrosis and Lymphoma

Anthony D. William, Angeline C.-H. Lee, Stéphanie Blanchard et al. · Journal of Medicinal Chemistry · 2011 · 198 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +17

Discovery of Kinase Spectrum Selective Macrocycle (16<i>E</i>)-14-Methyl-20-oxa-5,7,14,26-tetraazatetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8(27),9,11,16,21,23-decaene (SB1317/TG02), a Potent Inhibitor of Cyclin Dependent Kinases (CDKs), Janus Kinase 2 (JAK2), and Fms-like Tyrosine Kinase-3 (FLT3) for the Treatment of Cancer

Anthony D. William, Angeline C.-H. Lee, Kee Chuan Goh et al. · Journal of Medicinal Chemistry · 2011 · 100 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +16

Fragment-Based Ligand Design of Novel Potent Inhibitors of Tankyrases

Andreas Larsson, Anna Jansson, Fui Mee Ng et al. · Journal of Medicinal Chemistry · 2013 · 66 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +17

Structure-based design of oxygen-linked macrocyclic kinase inhibitors: discovery of SB1518 and SB1578, potent inhibitors of Janus kinase 2 (JAK2) and Fms-like tyrosine kinase-3 (FLT3)

Anders Poulsen, Anthony D. William, Stéphanie Blanchard et al. · Journal of Computer-Aided Molecular Design · 2012 · 42 citations

Pharmacy, Medicinal Chemistry, Pharmacology +17

Structure-based design of nitrogen-linked macrocyclic kinase inhibitors leading to the clinical candidate SB1317/TG02, a potent inhibitor of cyclin dependant kinases (CDKs), Janus kinase 2 (JAK2), and Fms-like tyrosine kinase-3 (FLT3)

Anders Poulsen, Anthony D. William, Stéphanie Blanchard et al. · Journal of Molecular Modeling · 2012 · 37 citations

Pharmacy, Medicinal Chemistry, Pharmacology +17